ImmuCell Corporation (ICCC), an animal health biologics company, announced preliminary first-quarter 2026 sales results, reflecting 28.4% revenue growth driven by its Tri-Shield product sales.
ImmuCell develops solutions to improve the survivability, health, and long-term performance of dairy and beef calves. The company's primary product line, First Defence, is for the treatment of scours, the most prevalent disease in neonatal calves.
First Defence Tri-Shield is a USDA-approved veterinary biologic product made by ImmuCell and is used in newborn dairy and beef calves as a preventative measure against scours.
For the first quarter, the firm reported preliminary net sales of $10.4 million from $8.1 million in the prior year.
Tri-Shield's first defence sales increased 38.5% to $7.9 million from $5.7 million a year ago, driven by seasonal demand from the cow-calf segment.
ImmuCell is scheduled to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to discuss the unaudited financial results for the quarter ended March 31, 2026. Bobbi Jo Brockmann, Senior Vice President, said: "As we move into the second and third quarters, demand shifts toward our year-round dairy customers."
ICCC has traded between $4.52 and $7.60 over the last year. The stock closed Wednesday's trade at $6.38, down 3.19%.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.